ClinicalTrials.gg
CompletedNCT03842397Updated Feb 26, 2021

OPtimisation of Surgical Repair for Treating Insufficiency of the MItral Valve - Safety Evaluation

An interventional study of Kephalios Device 1 in Mitral Valve Regurgitation, sponsored by Kephalios. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-26.

Sponsored by Kephalios · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Dec 2017, registered Feb 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Mitral Valve Insufficiency with a site in Austria — 6 open to participants now, 8 under way, none of them phase 3. Mitral Valve Insufficiency · Austria.

Started
2017
the only one that year
No phase
8 of 15
3 open now
Registered
4th of 15
by date
Lead sponsor
2 of 15
Kephalios

Among the 15 studies in Mitral Valve Insufficiency with a site in Austria, this one is the only one that started in 2017, is one of 8 with no phase, and was the 4th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

6 of the 15 studies in Mitral Valve Insufficiency with a site in Austria are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Mitral Valve Insufficiency with a site in Austria, or all of them as a file.
02

Study summary

The optimal surgical approach in functional mitral regurgitation (MI) was questioned in favour for prosthetic replacement due to the reduced risk of recurrent MI . However, adjustable mitral rings may provide an alternative . In this first-in-man trial, a novel balloon-adjustable mitral-ring was assessed regarding clinical safety and feasibility. 5 patients will be enrolled according to the inclusion/ exclusion criteria and subsequently implanted with the study device. Study visits will be performed preoperatively, perioperatively, at discharge, at 30 days, 3 months and 6 months. Primary outcome parameter will be morbidity and mortality at 30 days following implantation.

03

Conditions studied

  • Mitral Valve Regurgitation

Keywords

  • Mitral regurgitation
  • Mitral valve repair
  • Mitral annuloplasty
  • Adjustable annuloplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients

  1. with symptomatic severe Mitral Regurgitation (Carpentier's classification Type I or II P2) or in asymptomatic subjects with preserved Left Ventricle function and new onset of atrial fibrillation or pulmonary hypertension;
  2. with EuroScore II \< 4;
  3. with Left Ventricle ≥ 55%;
  4. with normal coronary angiogram (no significant lesions);
  5. in satisfactory condition, based on the physical exam and investigator's experience, with a above one year after the intervention;
  6. willing to sign the ;
  7. willing to undergo all medical follow-up, echocardiography examinations and laboratory tests planned for the clinical investigation.

Exclusion criteria

Exclusion Criteria:

Patients

  1. of age \< 18 years;
  2. who are pregnant;
  3. nursing mothers;
  4. who require undergoing MRI examination;
  5. involved in any other clinical investigation for drugs or devices;
  6. with previous cardiac surgery or diaphragmatic lesion or previous hepatic surgery;
  7. needing acute intervention;
  8. with active endocarditis (or having had active endocarditis in the last three months);
  9. with active myocarditis;
  10. with heavily calcified mitral annulus or mitral valve anatomy with a high risk of valve replacement instead of valve repair;
  11. needing any cardiac surgery other than mitral repair, tricuspid valve annuloplasty, pacemaker implantation (epicardial), exclusion of left appendage (with device or surgically) and Maze (or PVI) procedure;
  12. with severe pulmonary hypertension (systolic pulmonary artery pressure at rest >65 mmHg);
  13. with LV \< 55%;
  14. with creatinine level > 2.0 mg/100ml;
  15. with echocardiographic measurements predicting SAM (see specific echocardiography protocol);
  16. unable to take anticoagulation medications;
  17. with a known untreatable allergy to contrast media or nickel;
  18. with a major or progressive non-cardiac disease that, in the investigator's experience, results in a shorter than 1 year, or for whom the implant of the device produces an unacceptable increase of risk;
  19. having had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥ 30 days prior to the planned surgical procedure.
  20. unable to understand and sign the ICF in absence of legal protection
  21. unable to read and write
  22. anticipated ring size very small (26mm) or very large (36mm)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Implanted Patients

    Implantation of Kephalios Device 1

    Device: Kephalios Device 1

Interventions

  • DeviceKephalios Device 1

    The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3

06

What researchers measure

Primary outcomes

  1. Assessment of the safety of the Kephalios Device 1 in terms of mortality

    Valve-relatedness determined according to the STS/AATS/EACTS report - Akins, C. W., Miller, D. C., Turina, M. I., Kouchoukos, N. T., Blackstone, E. H., Grunkemeier, G. L., ... Lytle, B. W. (2008). Guidelines for Reporting Mortality and Morbidity After Cardiac Valve Interventions. The Annals of Thoracic Surgery, 85(4), 1490-1495. https://doi.org/10.1016/j.athoracsur.2007.12.082alve-relatedness determined according to the STS/AATS/EACTS report - Akins, C. W., Miller, D. C., Turina, M. I., Kouchoukos, N. T., Blackstone, E. H., Grunkemeier, G. L., ... Lytle, B. W. (2008). Guidelines for Reporting Mortality and Morbidity After Cardiac Valve Interventions. The Annals of Thoracic Surgery, 85(4), 1490-1495. https://doi.org/10.1016/j.athoracsur.2007.12.082

    Time frame: 30 days after implant

  2. Assessment of the safety of the Kephalios Device 1 in terms of morbidity

    Morbid events determined according to the STS/AATS/EACTS report - Akins, C. W., Miller, D. C., Turina, M. I., Kouchoukos, N. T., Blackstone, E. H., Grunkemeier, G. L., ... Lytle, B. W. (2008). Guidelines for Reporting Mortality and Morbidity After Cardiac Valve Interventions. The Annals of Thoracic Surgery, 85(4), 1490-1495. https://doi.org/10.1016/j.athoracsur.2007.12.082

    Time frame: 30 days after implant

Secondary outcomes

  1. Safety in terms of mortality

    Valve-relatedness determined according to the STS/AATS/EACTS report - Akins, C. W., Miller, D. C., Turina, M. I., Kouchoukos, N. T., Blackstone, E. H., Grunkemeier, G. L., ... Lytle, B. W. (2008). Guidelines for Reporting Mortality and Morbidity After Cardiac Valve Interventions. The Annals of Thoracic Surgery, 85(4), 1490-1495. https://doi.org/10.1016/j.athoracsur.2007.12.082

    Time frame: 3 and 6 months after implant

  2. Safety in terms of morbidity

    Morbid events determined according to the STS/AATS/EACTS report - Akins, C. W., Miller, D. C., Turina, M. I., Kouchoukos, N. T., Blackstone, E. H., Grunkemeier, G. L., ... Lytle, B. W. (2008). Guidelines for Reporting Mortality and Morbidity After Cardiac Valve Interventions. The Annals of Thoracic Surgery, 85(4), 1490-1495. https://doi.org/10.1016/j.athoracsur.2007.12.082

    Time frame: 3 and 6 months after implant

  3. Effectiveness in terms of increase of mitral leaflets coaptation

    through data objectively measured through echocardiography

    Time frame: in the immediate post-operative phase

  4. Effectiveness in terms of reduction of Mitral Regurgitation

    through data objectively measured through echocardiography

    Time frame: in the immediate post-operative phase

  5. Effectiveness in terms of absence of recurrent Mitral Regurgitation

    through data objectively measured through echocardiography

    Time frame: At hospital discharge or 30 days if subject is still hospitalized, and 6 months

07

Study locations

1 site
  • Medical University of Vienna - Department of Surgery, Division of Cardiac Surgery
    Vienna, 1090, Austria
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jul 2018, 6 months.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's 6 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2019
First posted
Feb 15, 2019
StartActual
Dec 30, 2017
Primary completionActual
Jul 2, 2018
CompletionActual
Nov 28, 2018
Last update
Feb 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03842397
Lead sponsor
Kephalios
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Dec 30, 2017
Primary completion
Jul 2, 2018
Completion
Nov 28, 2018
Last update
Feb 26, 2021

Study contacts

Martin ANDREAS, MBA,PhD
principal investigator · Medical University of Vienna - Department of Surgery, Division of Cardiac Surgery

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion